Budesonide gastro-resistant granules (Budenofalk) have been accepted for use within NHS Scotland by the Scottish Medicines Consortium (SMC). The approved indication is the induction of remission in patients with mild to moderate active Crohn’s disease affecting the ileum or ascending colon or both. Defibrotide (Defitelio), for the treatment of severe hepatic veno-occlusive disease, and fluticasone furoate and vilanterol (Relvar Ellipta), for the regular treatment of asthma in adults and adolescents aged 12 years and older, have also been accepted for use.
Canagliflozin (Invokana) is approved as an add-on therapy for type 2 diabetes, and sofosbuvir (Sovaldi) is accepted for the treatment of chronic hepatitis C in combination with other medicines; both have restrictions around their use.
Two medicines were not endorsed by the SMC because the marketing authorisation holder did not make a submission: avanafil (Spedra) for the treatment of erectile dysfunction in adult men; and natalizumab (Tysabri) as single disease-modifying therapy in highly active relapsing remitting multiple sclerosis.
Paclitaxel albumin (Abraxane) has not been recommended for use in combination with gemcitabine for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas because it was not considered cost-effective.
More information is available on the SMC website.
Citation: The Pharmaceutical Journal URI: 20065342
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com